Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia
2010

Lenalidomide Treatment for Myelodysplastic Syndrome

Sample size: 2 publication Evidence: low

Author Information

Author(s): Khalafallah Alhossain, Terry Brain

Primary Institution: Launceston General Hospital, Tasmania, Australia

Hypothesis

Different dosing regimens of lenalidomide may improve hematopoiesis in patients with intermediate to high-risk myelodysplastic syndrome.

Conclusion

Twice weekly lenalidomide dosing can lead to sustained hematological responses and improved quality of life in patients with myelodysplastic syndrome.

Supporting Evidence

  • Both patients achieved long-term transfusion independence after starting lenalidomide therapy.
  • One patient maintained a sustained erythroid response for over 10 months.
  • The modified dosing regimen was well tolerated without significant side effects.

Takeaway

This study shows that giving lenalidomide twice a week can help patients with a blood disorder feel better and not need blood transfusions.

Methodology

Two patients with myelodysplastic syndrome were treated with lenalidomide at a dose of 15 mg twice weekly.

Limitations

The study involves only two patients, limiting the generalizability of the findings.

Participant Demographics

Two Caucasian patients, one female aged 75 and one male aged 73.

Digital Object Identifier (DOI)

10.4084/MJHID.2010.012

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication